scholarly article | Q13442814 |
P50 | author | Simon Heeke | Q61118563 |
P2093 | author name string | Paul Hofman | |
Véronique Hofman | |||
Charles-Hugo Marquette | |||
Maryline Allegra | |||
Marius Ilié | |||
Virginie Tanga | |||
Christelle Bonnetaud | |||
Michel Poudenx | |||
Olivier Bordone | |||
Jonathan Benzaquen | |||
Jacques Boutros | |||
Salomé Lalvée | |||
Virginie Lespinet | |||
Carole Salacroup | |||
P2860 | cites work | An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 |
Functional consequence of the MET-T1010I polymorphism in breast cancer | Q35550045 | ||
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. | Q48507434 | ||
Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. | Q49417517 | ||
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. | Q50128100 | ||
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. | Q51760971 | ||
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer | Q57476349 | ||
TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting | Q60301211 | ||
Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France) | Q90099242 | ||
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study | Q90215699 | ||
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab | Q90788586 | ||
Liquid biopsy and minimal residual disease - latest advances and implications for cure | Q91845060 | ||
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium | Q92493647 | ||
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy | Q92578527 | ||
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer | Q93109964 | ||
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers | Q93367319 | ||
P433 | issue | 1 | |
P921 | main subject | lung carcinoma | Q18556110 |
P304 | page(s) | 87 | |
P577 | publication date | 2020-02-17 | |
P1433 | published in | Journal of Translational Medicine | Q15716664 |
P1476 | title | Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution | |
P478 | volume | 18 |
Q98948993 | Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives | cites work | P2860 |
Search more.